The University of Warwick spinout is developing treatments for respiratory conditions such as influenza.
VirionHealth, a UK-based respiratory therapeutics spinout from University of Warwick, has secured series A funding of up to £13m ($17.1m) from bioscience investment firm Abingworth.
Founded in 2017, VirionHealth is researching how defective genomes created as a byproduct of respiratory viruses could help defeat and prevent the illness itself.
The spinout hopes the approach would provide a more comprehensive and flexible remedy for infections such as influenza or respiratory syncytial virus.
VirionHealth is based on research by Nigel Dimmock and…
